Condition

Hypereosinophilia (3)

Angiostrongylosis (1)

Anti-Asthmatic Agents (1)

Hematologic Diseases (1)

Hypereosinophilic Syndrome (1)

Leukocyte Disorders (1)

Respiratory System Agents (1)

Overall Status

Active, not recruiting (1)

Completed (1)

Recruiting (1)

Phase

phase 2/phase 3 (1)

phase 3 (1)

Sponsor

GlaxoSmithKline (1)

National Institute of Allergy and Infectious Diseases (NIAID) (1)

University Hospital Center of Martinique (1)

Collaborator

AstraZeneca (1)

Hospital Center of Basse-Terre (Guadeloupe) (1)

Hospital Center of Cayenne (French Guiana) (1)

Hospital Center of Saint-Laurent du Maroni (French Guiana) (1)

University Hospital Center of Pointe-a-Pitre/Abymes (Guadeloupe) (1)

Intervention

benralizumab (1)

biopsy (1)

mepolizumab (1)

parasitic serologies (1)

placebo (1)

Study Documents

Intervention Type

drug (2)

biological (1)

other (1)

procedure (1)

Funder Type

Industry (1)

NIH (1)

Other (1)

Study Type

Interventional (2)

Observational (1)

hypereosinophilia

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases Trial run by the NIAID (benralizumab, Placebo)

Active, not recruiting

Has Results

Respiratory System Agents
+4 more

benralizumab
Placebo

Bethesda, Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pi

Jan 20, 2022

Research for Angiostrongylus Cantonensis and Costaricensis in

Recruiting

Angiostrongylosis
Hypereosinophilia

Parasitic serologies
Biopsy

Fort-de-France, France

CHU of Martinique

Dec 10, 2020

Hypereosinophilia, Hypereosinophilic Syndrome Trial in Worldwide (mepolizumab)

Completed

Hypereosinophilia
Hypereosinophilic Syndrome

mepolizumab

San Diego, California
+28 more

May 1, 2020